RESUMO
In this report we present the results of a collaborative study for the preparation and calibration of a replacement International Standard (IS) for Haemophilus influenzae type b polysaccharide (polyribosyl ribitol phosphate; 5-d-ribitol-(1 â 1)-ß-d-ribose-3-phosphate; PRP). Two candidate preparations were evaluated. Thirteen laboratories from 9 different countries participated in the collaborative study to assess the suitability and determine the PRP content of two candidate standards. On the basis of the results from this study, Candidate 2 (NIBSC code 12/306) has been established as the 2nd WHO IS for PRP by the Expert Committee of Biological Standards of the World Health Organisation with a content of 4.904 ± 0.185mg/ampoule, as determined by the ribose assays carried out by 11 of the participating laboratories.
Assuntos
Haemophilus influenzae tipo b/química , Polissacarídeos Bacterianos/normas , Polissacarídeos/normas , Organização Mundial da Saúde , Cápsulas Bacterianas/química , Bioensaio/normas , Calibragem , Cromatografia Líquida de Alta Pressão , Estabilidade de Medicamentos , Vacinas Anti-Haemophilus/química , Vacinas Anti-Haemophilus/normas , Concentração de Íons de Hidrogênio , Cooperação Internacional , Laboratórios/normas , Fósforo/análise , Polissacarídeos/análise , Polissacarídeos Bacterianos/análise , Padrões de Referência , Reprodutibilidade dos Testes , Ribose/análiseRESUMO
Current Haemophilus influenzae b conjugate vaccines (Hib), which are made of purified capsular polysaccharide (poly-ribosyl-ribitol-phosphate; PRP) conjugated to a carrier protein, are almost completely evaluated by physico-chemical methods to ensure the integrity and stability of the vaccine and consistency of manufacture of batches. The absence of a potency assay makes the quantification of total PRP content (in SI units) and of % free polysaccharide in final fills or bulk components of Hib vaccines critical release tests for both manufacturers and national control authorities. Here we describe a simple and sensitive Enzyme-Linked Immuno-sorbent Assay (ELISA) which has been developed to quantify total and free PRP content in Hib-TT vaccine alone or when in combination with other vaccines. The assay is robust, specific and highly sensitive.
Assuntos
Ensaio de Imunoadsorção Enzimática/métodos , Vacinas Anti-Haemophilus/química , Polissacarídeos/análise , Toxoide Tetânico/química , Vacinas Combinadas/química , Limite de Detecção , Reprodutibilidade dos TestesRESUMO
No vaccines are currently licensed against Group B streptococcus (GBS), an important cause of morbidity and mortality in babies and adults. Using a mouse model, and in vitro opsonophagocytosis and colonisation assays, we evaluated the potential of a sublingually-administered polysaccharide-conjugate vaccine against GBS serotype III. Sublingual immunisation of mice with 10 µg of GBS conjugate vaccine once a week for 5 weeks induced a substantial systemic IgG anti-polysaccharide response which was similar to the level induced by subcutaneous immunsation. In addition, sublingual immunisation also induced mucosal (IgA) antibody responses in the mouth, intestines and vagina. Immune sera and intestinal washes were functionally active at mediating killing of the homologous GBS serotype III in an opsonophagocytosis assay. In addition, intestinal and vaginal washes inhibited the colonisation of mouse vaginal epithelial cells by the vaccine homologous strain. These results suggest that, in addition to the induction of high levels of IgG antibodies that could be transduced from the immunised mother to the foetus to protect the newborn against GBS infection, sublingual immunisation can elicit a substantial mucosal antibody response which might play an important role in the prevention of GBS colonisation in immunised women, thereby eliminating the risk of GBS transmission from the mother to the baby during pregnancy or at birth.
Assuntos
Infecções Estreptocócicas , Toxoide Tetânico , Anticorpos Antibacterianos , Formação de Anticorpos , Células Epiteliais , Feminino , Humanos , Soros Imunes , Imunoglobulina A , Imunoglobulina G , Polissacarídeos , Gravidez , Sorogrupo , Infecções Estreptocócicas/prevenção & controle , Streptococcus agalactiae , Vacinação , Vacinas ConjugadasRESUMO
The use of Soluplus® polymeric micelles as a novel adjuvant for tetanus toxoid (TTxd) in transcutaneous immunisation was evaluated. TTxd was added to Soluplus® polymeric micelles to form TTxd-Soluplus® nano-aggregates with a size of 68nm. Non-adjuvanted TTxd commonly induces very poor antibody response by the transcutaneous route. However, in this study, the use of TTxd-Soluplus® resulted in a significant increase in the antibody response to TTxd, which was similar to that induced in the presence of CPG-oligodeoxynucleotides (CPG-ODNs) adjuvant. The toxin neutralising potency of the immune sera induced by TTxd-Soluplus® was also much stronger than that from TTxd alone, in a passive transfer experiment in mice. Soluplus® also enhanced the immunogenicity of the toxoid when TTxd-Soluplus® was stored at 4°C for 4weeks, but not at higher temperatures. Confocal microscopy imaging showed a much higher uptake of TTxd in the epidermis and dermis layers of the skin when it was associated with Soluplus®, suggesting that the mechanism for Soluplus® adjuvanticity is through enhanced uptake of the TTxd through the skin. Overall, our findings demonstrated that Soluplus® is an effective novel adjuvant for transcutaneous immunisation.
Assuntos
Adjuvantes Imunológicos/administração & dosagem , Formação de Anticorpos , Antitoxinas/sangue , Nanopartículas/administração & dosagem , Polietilenoglicóis/administração & dosagem , Polivinil/administração & dosagem , Toxoide Tetânico/imunologia , Administração Cutânea , Animais , Anticorpos Neutralizantes/sangue , Modelos Animais de Doenças , Feminino , Imunização Passiva , Camundongos , Ratos Sprague-Dawley , Tétano/prevenção & controle , Toxoide Tetânico/administração & dosagemRESUMO
The immunogenicity and physico-chemical characteristics of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III, were evaluated. The level and functional activity of serotype-specific antibody responses induced by monovalent and combined formulations were investigated using a mouse model and in vitro opsonophagocytosis assay. Molecular sizing of the conjugates and integrity of the intermediate components were evaluated by optical spectroscopy and size exclusion chromatography. All three serotypes induced substantial antibody responses which were functionally active. Combining the three serotypes did not seem to affect the antibody responses to individual serotypes, except when given at high dose, where the IgG response to serotype III but not the opsonophagocytic activity was slightly reduced compared to monovalent administration.
Assuntos
Infecções Estreptocócicas/prevenção & controle , Vacinas Estreptocócicas/imunologia , Streptococcus agalactiae/imunologia , Animais , Anticorpos Antibacterianos/sangue , Técnicas de Tipagem Bacteriana , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Opsonizantes/sangue , Fagocitose , Sorotipagem , Vacinas Estreptocócicas/administração & dosagem , Vacinas Conjugadas/administração & dosagem , Vacinas Conjugadas/imunologiaRESUMO
The immunogenicity, structure and stability of a combined conjugate vaccine against Haemophilus influenzae type b and meningococcal serogroup C (Hib/MenC) were investigated. A rat model for immunogenicity showed that antibody responses to Hib and MenC in the combined vaccine were similar to or higher than those of individual conjugates given alone, or concomitantly at separate sites. At elevated temperatures, the combination vaccine was slightly more stable than a monovalent Hib-TT vaccine, with respect to molecular size, which could be attributed to differences in the formulations. Following 5 weeks incubation at 56 degrees C, there was some dissociation of high molecular weight conjugate without significant loss of saccharide integrity; however, this did not significantly affect the vaccine immunogenicity, demonstrating the stability of this lyophilized vaccine.
Assuntos
Vacinas Anti-Haemophilus/química , Vacinas Anti-Haemophilus/imunologia , Toxoide Tetânico/química , Toxoide Tetânico/imunologia , Animais , Anticorpos Antibacterianos/sangue , Feminino , Imunoglobulina G/sangue , Vacinas Meningocócicas/imunologia , Ratos , Ratos Sprague-Dawley , Temperatura , Vacinas Combinadas/química , Vacinas Combinadas/imunologiaRESUMO
The physico-chemical characteristics and immunogenicity of a candidate vaccine against otitis media, prepared from recombinant lipidated outer membrane proteins (rLP4 and rLP6) from non-typeable Haemophilus influenzae (NTHi) and of the ubiquitous cell surface protein UspA2 from Moraxella catarrhalis, were evaluated. Optical spectroscopy, size exclusion chromatography and gel electrophoresis were used to characterise the purified protein components and assess their purity and molecular sizes. The results showed that the three proteins were highly purified. Possible dimers in rLP4, dimers and multimers in rLP6 and UspA2 were detected. Small amounts of rLP4 and rLP6 dimers and most of UspA2 complexes remained tightly bound even after SDS treatment under reducing conditions. Immunogenicity studies showed that all proteins induced substantial antibody responses in mice immunised with AlPO4-adsorbed rLP4, rLP6 or UspA2 or a combination of these proteins. However, combination of these proteins resulted in a reduced response to rLP4 and rLP6, but not to UspA2, suggesting interference between these proteins which should be taken into consideration during the development and evaluation of this vaccine.
Assuntos
Vacinas Bacterianas/química , Vacinas Bacterianas/imunologia , Vacinas Anti-Haemophilus/química , Vacinas Anti-Haemophilus/imunologia , Moraxella catarrhalis/imunologia , Adjuvantes Imunológicos/farmacologia , Compostos de Alumínio/farmacologia , Animais , Western Blotting , Proliferação de Células , Fenômenos Químicos , Físico-Química , Cromatografia em Gel , Dicroísmo Circular , Citocinas/biossíntese , Eletroforese em Gel de Poliacrilamida , Imunidade Celular/efeitos dos fármacos , Imunoglobulina G/análise , Imunoglobulina G/imunologia , Proteínas de Membrana/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Microscopia de Fluorescência , Peso Molecular , Fosfatos/farmacologia , Baço/citologia , Baço/imunologia , Baço/metabolismo , Vacinas Combinadas/química , Vacinas Combinadas/imunologia , Vacinas Sintéticas/química , Vacinas Sintéticas/imunologiaRESUMO
Following the reduction in efficacy of Hib-TT vaccines in the primary immunization schedule observed in the UK between 1999 and 2003, batches of vaccine manufactured by two different companies were retrospectively examined by the National Institute for Biological Standards and Control. The study evaluated 41 batches of the Hib-TT vaccines manufactured between 1994 and 2003, assaying potency (total PRP saccharide content), integrity (% free saccharide), consistency (molecular sizing), and immunogenicity, as well as reviewing data previously obtained at the time of release. The study indicated the stability of the lyophilized final fill vaccines to extend well past their assigned shelf-lives, and found no trends in the endotoxin content, total saccharide or % free saccharide content. A trend towards slightly larger conjugates was observed over time in Hib-TT A, evidenced in both the manufacturer's data obtained at the time that samples were submitted for testing and in data obtained from the retrospective analysis. The study confirmed that that there had been no significant change in the quality of the Hib vaccines that could possibly account for the change reported in their protective efficacy in the UK. The study also demonstrated the value of independent testing of vaccines from the time of licensure and in the ongoing monitoring and re-examination of selected batches, as necessary, to assure their continuing quality, safety and consistency.